The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

MODERATOR: Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

In the early 1980s, men and women in the prime of their lives began arriving at Walter Reed Medical Center, wrecked by a disease for which we had no name, no cause and no hope. As an infectious ...

Ruanne Barnabas grew up in Durban, South Africa, during a time of “deep inequity in health, opportunity, and justice”.

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...

A federal jury in Fort Lauderdale has convicted two Maryland brothers of orchestrating a multimillion-dollar scheme to buy and resell<a class="excerpt-read-more" href=" More ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks ...